Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Doppelgänger

#136 Elon Musk 🦅 Twitter | 🧂Nestlé kauft Ankerkraut | Secunet | 📈 Chartanalyse | Sweat Equity | 🥶 Venture Winter

15 Apr 2022

Description

Elon Musk will Twitter kaufen und von der Börse nehmen. Ankerkraut hat den Shitstorm der Woche. Pip wurden nach Secunet gefragt und was er von Chartanalysen hält. Wir sprechen über Sweat Equity und einen möglichen Venture Winter. Philipp Glöckler (https://twitter.com/gloeckler) und Philipp Klöckner (https://twitter.com/pip_net) sprechen heute über: (00:00:20) Elon x Twitter (00:07:30) Twitter kann ohne Elon, Elon nicht ohne Twitter (00:14:00) Flip In Poison Pill (00:16:30) Flip Over Poison Pill (00:21:00) Wer sonst kauft Twitter (00:27:20) Nestle kauft Ankerkraut (00:42:00) Private Equity Performance Metriken (00:54:20) ETFs, Einzelaktien, Zinseszins (00:58:00) Secunet AG (01:04:00) Astrologie x Chartanalysen (01:09:00) Sweat Equity (01:18:00) Inflation über 15%? Shownotes: Sequoia Capital’s 56 Slide Presentation Of Doom https://techcrunch.com/2008/10/10/sequoia-capitals-56-slide-powerpoint-presentation-of-doom/ ‘The Brutal Reality’: Startups Face Great Uncertainty—Again https://www.theinformation.com/articles/the-brutal-reality-startups-face-great-uncertainty-again The global economy’s growing risks: stagflation, refugees and lockdowns https://www.ft.com/content/0f7945f5-b269-4d13-9151-c1ac9ec6fddc Doppelgänger Tech Talk Podcast Sheet https://doppelgaenger.io/sheet/ Earnings & Event Kalender https://www.doppelgaenger.io/kalender/ Disclaimer https://www.doppelgaenger.io/disclaimer/ Post Production by Jan Wagener https://twitter.com/JanAusDemOff Sponsoring: https://www.doppelgaenger.io/sponsoring/

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.